CIP
BPMC

Chartwell Investment Partners’s Blueprint Medicines BPMC Stock Holding History

Chartwell Investment Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,362
Closed -$957K – 407
2020
Q1 		$957K Buy
16,362
+4,358
+36% +$280K 0.04% 321
2019
Q4 		$962K Sell
12,004
-11,771
-50% -$881K 0.03% 358
2019
Q3 		$1.75M Hold
23,775
– – 0.06% 327
2019
Q2 		$2.24M Buy
23,775
+4,219
+22% +$348K 0.07% 310
2019
Q1 		$1.56M Buy
+19,556
New +$1.45M 0.05% 357

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Chartwell Investment Partners's BPMC Position: Q2 2020 in Review

Chartwell Investment Partners sold out of Blueprint Medicines (BPMC) in Q2 2020, closing a stake of 16,362 shares — an estimated $957K sold.

Chartwell Investment Partners first reported a position in BPMC in Q1 2019 and held it in 5 quarters. The position peaked at $2.24M in Q2 2019. 234 funds tracked by Wall St. Rank hold BPMC as of Q2 2020.

  • Chartwell Investment Partners reported no remaining Blueprint Medicines position as of Q2 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 16,362 Blueprint Medicines shares in Q2 2020, an estimated $957K.
  • Chartwell Investment Partners first reported a position in Blueprint Medicines in Q1 2019 and held it in 5 quarters.
  • Chartwell Investment Partners's Blueprint Medicines position peaked at $2.24M in Q2 2019.
  • 234 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2020.

Based on Chartwell Investment Partners's 13F filing for Q2 2020, filed 29 Jul 2020.